Abstract
Immune checkpoint inhibitors have shown great promise in treating patients with mismatch repair deficient/microsatellite instability high (dMMR/MSI-H) colorectal cancer (CRC). Although single-agent pembrolizumab has been approved for first-line treatment of...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have